TABLE 1.
Seroreactivities in each assay
| Assay | No. of specimens seroreactive/total no. (%)a
|
||||
|---|---|---|---|---|---|
| HIV+ KS+ (n = 27) | HIV− KS+ (n = 2) | HIV+ KS− (n = 23) | RF+ (n = 10)b | Control (n = 30) | |
| Lytic-mIFA | 27/27 (100) | 2/2 (100) | 15/23 (65) | 5/10 (50) | 4/30 (13) |
| K8.1-IFA | 27/27 (100) | 2/2 (100) | 15/23 (65) | 4/8 (50) | 2/30 (6.7) |
| K8.1-ELISA | 23/27 (85) | 1/2 (50) | 7/23 (30) | 3/10 (30) | 0/30 (0) |
| ORF65-ELISA | 23/27 (85) | 0/2 (0) | 7/23 (30) | 2/10 (20) | 0/30 (0) |
| Latent-mIFA | 18/27 (67) | 1/2 (50) | 6/23 (26) | 0/8 (0) | 0/30 (0) |
| ORF73-IFA | 17/27 (63) | 1/2 (50) | 6/23 (26) | 0/9 (0) | 0/30 (0) |
| ORF73-IFA/K8.1-IFAc | 17/27 (63) | 1/2 (50) | 6/15 (40) | 0/4 (0) | 0/2 (0) |
a
n, number of serum specimens in each group. Data are the number of serum specimens positive/number of specimens tested.
b
Due to nonspecific reactions against cellular components at a serum dilution 1:20, seroreactivities of two specimens in the RF+ group are not available for some of the IFAs. These sera were negative at a serum dilution of 1:40 in IFAs.
c
The data in the last row indicate the number of serum specimens positive by ORF73-IFA/number of K8.1-IFA positive specimens (%).